Almirall Future Growth
Future criteria checks 4/6
Almirall is forecast to grow earnings and revenue by 54% and 9.8% per annum respectively. EPS is expected to grow by 54.1% per annum. Return on equity is forecast to be 7.2% in 3 years.
Key information
54.0%
Earnings growth rate
54.1%
EPS growth rate
Pharmaceuticals earnings growth | 19.5% |
Revenue growth rate | 9.8% |
Future return on equity | 7.2% |
Analyst coverage | Good |
Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,205 | 92 | 130 | 236 | 9 |
12/31/2025 | 1,086 | 54 | 94 | 195 | 9 |
12/31/2024 | 975 | 17 | 4 | 148 | 9 |
9/30/2024 | 953 | -45 | -23 | 149 | N/A |
6/30/2024 | 932 | -35 | -115 | 103 | N/A |
3/31/2024 | 915 | -39 | -48 | 116 | N/A |
12/31/2023 | 899 | -38 | -66 | 93 | N/A |
9/30/2023 | 907 | 7 | -23 | 101 | N/A |
6/30/2023 | 898 | -11 | 23 | 156 | N/A |
3/31/2023 | 882 | -8 | 37 | 154 | N/A |
12/31/2022 | 879 | 4 | 39 | 155 | N/A |
9/30/2022 | 864 | 9 | 105 | 177 | N/A |
6/30/2022 | 856 | 29 | 98 | 180 | N/A |
3/31/2022 | 843 | -50 | 82 | 159 | N/A |
12/31/2021 | 837 | -41 | 163 | 234 | N/A |
9/30/2021 | 814 | -22 | 204 | 288 | N/A |
6/30/2021 | 809 | -11 | 145 | 196 | N/A |
3/31/2021 | 790 | 55 | 122 | 198 | N/A |
12/31/2020 | 814 | 74 | 36 | 113 | N/A |
9/30/2020 | 849 | 63 | 72 | 212 | N/A |
6/30/2020 | 872 | 86 | 49 | 194 | N/A |
3/31/2020 | 926 | 121 | 158 | 296 | N/A |
12/31/2019 | 911 | 106 | 141 | 276 | N/A |
9/30/2019 | 858 | 85 | -410 | 190 | N/A |
6/30/2019 | 884 | 88 | -368 | 181 | N/A |
3/31/2019 | 789 | 80 | -463 | 138 | N/A |
12/31/2018 | 811 | 78 | -456 | 143 | N/A |
9/30/2018 | 714 | -111 | 105 | 170 | N/A |
6/30/2018 | 730 | -179 | N/A | 133 | N/A |
3/31/2018 | 687 | -293 | N/A | 82 | N/A |
12/31/2017 | 677 | -304 | N/A | 6 | N/A |
9/30/2017 | 735 | -128 | N/A | -89 | N/A |
6/30/2017 | 755 | -78 | N/A | -13 | N/A |
3/31/2017 | 821 | 73 | N/A | 12 | N/A |
12/31/2016 | 822 | 75 | N/A | 105 | N/A |
9/30/2016 | 778 | 162 | N/A | 151 | N/A |
6/30/2016 | 743 | 154 | N/A | 122 | N/A |
3/31/2016 | 721 | 111 | N/A | 114 | N/A |
12/31/2015 | 738 | 132 | N/A | 171 | N/A |
9/30/2015 | 783 | 479 | N/A | 761 | N/A |
6/30/2015 | 802 | 488 | N/A | 748 | N/A |
3/31/2015 | 842 | 481 | N/A | 768 | N/A |
12/31/2014 | 828 | 448 | N/A | 647 | N/A |
9/30/2014 | 868 | -13 | N/A | 56 | N/A |
6/30/2014 | 849 | -32 | N/A | 52 | N/A |
3/31/2014 | 845 | -33 | N/A | 62 | N/A |
12/31/2013 | 825 | -34 | N/A | 67 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: E2Z is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: E2Z is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: E2Z is expected to become profitable in the next 3 years.
Revenue vs Market: E2Z's revenue (9.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: E2Z's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: E2Z's Return on Equity is forecast to be low in 3 years time (7.2%).